Clinical trials: Hypertrophic Cardiomyopathy
Healthy, Hypertrophic Cardiomyopathy
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation.
- Conditions
- Healthy, Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
- Trial name
- NCT00001632
- Where
- United States
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Rare Diseases, Fabry Disease
Evaluation of HEArt invoLvement in Patients With FABRY Disease
This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.
- Conditions
- Rare Diseases, Fabry Disease, Fabry Disease, Cardiac Variant, Hypertrophic Cardiomyopathy
- Trial name
- HEAL-FABRY (NCT03362164)
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Wuerzburg University Hospital
Hypertrophic Cardiomyopathy
Paced Dyssynchrony and Myocardial Perfusion IN apiCal Hcm
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. A relatively common subgroup of HCM patients have apical HCM - a type of heart muscle disease that causes abnormal muscle thickening towards the tip…
- Trial name
- PINCHcm (NCT04231032)
- Testing
- Asynchronous dual chamber pacing (DOO) with paced ventricular activation, Asynchronous atrial pacing (AOO) with intrinsic ventricular activation
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Barts & The London NHS Trust
Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM)
Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy
The goal of this clinical trial is designed to characterise the safety, tolerability, efficacy, and PK of Aom0304 across oHCM and nHCM populations and to inform dose selection for future Phase 3 development.
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM), Non-obstructive HCM (nHCM)
- Trial name
- NCT07675668
- Testing
- QG101-23-0 enteric coated capsule (60/120/240/360 mg BID), QG101-23-0 enteric coated capsule (120/240/360/480mg BID)
- Volunteers
- 56 people
- Sponsor
- Amckaus PTY LTD.
Hypertrophic Cardiomyopathy (HCM)
One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance
This is a multi-center, observational study aiming to establish a precision diagnosis scheme and multi-dimensional risk prediction models for Hypertrophic Cardiomyopathy (HCM). The study plans to enroll 10000 adult HCM patients.
- Trial name
- NCT07336290
- Volunteers
- 10,000 people
- Sponsor
- Minjie Lu
Nonobstructive Hypertrophic Cardiomyopathy
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.
- Trial name
- NCT07867288
- Testing
- HTX-001
- Where
- 3 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Haya Therapeutics, Inc.
Hypertrophic Cardiomyopathy
Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy
The aim of this randomized trial is to compare the improvement in exercise capacity among patients with highly symptomatic hypertrophic obstructive cardiomyopathy despite optimal medical treatment who undergo alcohol septal…
- Trial name
- AMARONE (NCT04684290)
- Testing
- Alcohol Septal Ablation, Surgical Septal Myectomy
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- St. Antonius Hospital
Hypertrophic Cardiomyopathy
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by…
- Trial name
- MyPEAK-1 (NCT05836259)
- Testing
- TN-201
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tenaya Therapeutics
Hypertrophic Obstructive Cardiomyopathy
Transapical Beating-heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy
The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy.
- Trial name
- NCT05332691
- Testing
- Transapical beating-heart septal myectomy
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Xiang Wei
Obstructive Hypertrophic Cardiomyopathy
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac…
- Trial name
- NCT06116968
- Testing
- Aficamten
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- Corxel Pharmaceuticals
Hypertrophic Cardiomyopathy
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
The purpose of this research study is to understand more about various heart rhythms (electrical problems) in persons with hypertrophic cardiomyopathy with and without sleep apnea.
- Trial name
- NCT04112290
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Mayo Clinic
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
The purpose of this study was to understand the epidemiological status of Fabry in patients with hypertrophic cardiomyopathy or left ventricular hypertrophy through multi-center early identification of high-risk patients in…
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Fabry Disease
- Trial name
- SEARCH (NCT06169358)
- Where
- China
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Qilu Hospital of Shandong University
Cardiomyopathy, Hypertrophic
The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
This study will examine how heart stiffness and a weak atrium affect exercise capacity and symptoms in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT00074880
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Non-obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
- Trial name
- IMPROVE-HCM (NCT04826185)
- Testing
- IMB-1018972
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 67 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
Hypertrophic Cardiomyopathy (HCM)
Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy
This study will review medical information collected on children and adolescents with hypertrophic cardiomyopathy (HCM) to try to identify risk factors for arrhythmias (abnormal heart rhythms) in these patients and better guide…
- Trial name
- NCT00753233
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy
Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
In this trial, the investigators will assess the effect of metoprolol in patients with hypertrophic cardiomyopathy who underwent alcohol septal ablation.
- Trial name
- NCT04133532
- Testing
- Metoprolol
- Where
- Czechia
- Volunteers
- 22 people
- Sponsor
- University Hospital, Motol
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated
MRI Sequence and Imaging Protocol Development
The purpose of this study is to develop imaging protocols when using cardiovascular magnetic resonance (CMR) to assess cardiac functions, morphology and tissue characterization.
- Conditions
- Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated, Left Ventricular Hypertrophy, Ischemic Heart Disease
- Trial name
- BikeMRI (NCT03040947)
- Testing
- Cardiovascular Magnetic Resonance
- Where
- Singapore
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Heart Centre Singapore
Hypertrophic Cardiomyopathy
Use of Magnetic Field Mapping in the Evaluation of Patients With Hypertrophic Heart Disease (Thick Heart Muscle)
The purpose of this research study is to further establish the diagnostic use of magnetocardiography (MCG) in patients with hypertrophic cardiomyopathy (HCM). The use of MCG has not been extensively studied in these patients.
- Trial name
- NCT00574821
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Friedreich Ataxia, Cardiomyopathies
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA).
- Conditions
- Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
- Trial name
- NCT05302271
- Testing
- AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN, Prednisone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Weill Medical College of Cornell University
Hypertrophic Cardiomyopathy
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Validation of validity, superiority, and safety of data analysis results using AT-Patch compared to 48-hour Holter test results Number of subjects: 100 (including 10% dropout rate) Performance and safety were verified by…
- Trial name
- ATP-HCM (NCT06873828)
- Testing
- ATP-C135, ATP-C75
- Volunteers
- 100 people
- Sponsor
- Yonsei University